Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature
European Journal of Clinical Microbiology & Infectious Diseases(2024)
Abstract
Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2–7). Median time between two reinjections was 57 days (IQR 28–82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9
MoreTranslated text
Key words
Dalbavancin,Suppressive therapy,Prosthetic joint infection,Vascular graft infection,Dosage
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined